American Diabetes Association
DC22-1710 PGT_Cal_Intake_Diabetes_Care_Brief_Report_-_appendix.docx (157.75 kB)

Tirzepatide reduces appetite, energy intake and fat mass in people with T2D

Download (157.75 kB)
posted on 2023-03-01, 19:11 authored by Tim Heise, J Hans DeVries, Shweta Urva, Jing LiJing Li, Edward J. Pratt, Melissa K. Thomas, Kieren J. Mather, Chrisanthi A. Karanikas, Julia Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun


OBJECTIVE: To evaluate effects of tirzepatide on body composition, appetite and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide.

RESEARCH DESIGN AND METHODS: In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N=45), semaglutide 1 mg (N=44) and placebo (N=28) on body weight and composition, appetite, and energy intake were assessed at baseline and Week 28.

RESULTS: Tirzepatide treatment demonstrated significant reductions in body weight compared to placebo and semaglutide, resulting in greater fat mass reduction. Tirzepatide and semaglutide significantly reduced appetite vs placebo. Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide. 

CONCLUSIONS: Differences in energy intake during ad libitum lunch were not sufficient to explain the different weight outcomes. Further evaluation is needed to assess mechanistic differences related to tirzepatide actions on 24-hour energy intake, substrate utilization and energy expenditure.


Eli Lilly and Company


Usage metrics

    Diabetes Care


    Ref. manager